TITLE

Service development free papers

PUB. DATE
April 2005
SOURCE
Gut;Apr2005 Supplement 2, Vol. 54, pA26
SOURCE TYPE
Academic Journal
DOC. TYPE
Abstract
ABSTRACT
The article presents information on abstracts related to human biology. An abstract presents information on the financial constraints limiting the prescription of infliximab in Crohn's disease. Infliximab, a chimeric monoclonal antibody against TNF-α, has been licensed for use in Great Britain since 1997 for patients with Crohn's disease. The treatment is recommended for use in a specific group of patients with the disease, as outlined in the National Institute of Clinical Excellence guidelines published in 2002. It remains unclear whether there are any factors preventing or limiting gastroenterologists from prescribing infliximab in these patients. The aim was to identify the factors limiting the prescription of infliximab in patients with Crohn's disease and to determine any regional variations in the frequency of its prescription.
ACCESSION #
16567961

 

Related Articles

  • Spotlight on Infliximab in Crohn Disease and Rheumatoid Arthritis. Siddiqui, M Asif A; Scott, Lesley J // BioDrugs;2006, Vol. 20 Issue 1, p67 

    Infliximab (Remicade) is a chimeric monoclonal antibody against tumor necrosis factor (TNF)-α that has shown efficacy in Crohn disease and rheumatoid arthritis with a disease-modifying activity and rapid onset of action. It is administered intravenously, generally in a schedule with initial...

  • Comparison of the effectiveness of infliximab and adalimumab in preventing postoperative recurrence in patients with Crohn's disease: an open-label, pilot study. Tursi, A.; Elisei, W.; Picchio, M.; Zampaletta, C.; Pelecca, G.; Faggiani, R.; Brandimarte, G. // Techniques in Coloproctology;Nov2014, Vol. 18 Issue 11, p1041 

    Background: Endoscopic and clinical recurrence of Crohn's disease (CD) appears in up to 80 and 30 % of patients, respectively, 1 year after surgery. Both infliximab (IFX) and adalimumab (ADA) have been demonstrated to be effective in reducing the possibility of recurrence after surgery, but...

  • Clinical pharmacokinetics and use of infliximab. Klotz, Ulrich; Teml, Alexander; Schwab, Matthias // Clinical Pharmacokinetics;2007, Vol. 46 Issue 8, p645 

    Tumor necrosis factor-α (TNFα) is a key proinflammatory cytokine involved in chronic inflammatory diseases. Infliximab, a chimeric (human-murine) monoclonal IgG1 anti-TNFα antibody, is used in the treatment of Crohn's disease (including fistulising disease) and rheumatoid arthritis (in...

  • Infliximab and newly diagnosed neoplasia in Crohn's disease: a multicentre matched pair study. Biancone, L.; Orlando, A.; Kohn, A.; Colombo, E.; Sostegni, R.; Angelucci, E.; Rizzello, F.; Castiglione, F.; Benazzato, I.; Papi, C.; Meucci, G.; Riegler, G.; Petruzziello, C.; Mocciaro, F.; Geremia, A.; Calabrese, E.; Cottone, M.; Pallone, F. // Gut;Feb2006, Vol. 55 Issue 2, p228 

    Background and aims: The widespread use of anti-tumour necrosis factor α antibody (Infliximab) in Crohn's disease (CD) raises concerns about a possible cancer risk in the long term. In a matched pair study, we assessed whether Infliximab is associated with an increased risk of neoplasia....

  • Infliximab: A Review of its Use in Crohn’s Disease and Rheumatoid Arthritis. Siddiqui, M. Asif A.; Scott, Lesley J. // Drugs;2005, Vol. 65 Issue 15, p2179 

    Infliximab (Remicade®) is a chimeric monoclonal antibody against tumour necrosis factor (TNF)-α that has shown efficacy in Crohn's disease and rheumatoid arthritis with a disease-modifying activity and rapid onset of action. It is administered intravenously, generally in a schedule with...

  • Adalimumab: In Crohn's Disease. Plosker, Greg L.; Lyseng-Williamson, Katherine A. // BioDrugs;2007, Vol. 21 Issue 2, p125 

    â–´ Adalimumab is a subcutaneously administered, recombinant, human IgG1 monoclonal antibody specific for human tumor necrosis factor (TNF). â–´ The clinical efficacy and safety of adalimumab in patients with moderate to severe Crohn's disease has been demonstrated in four pivotal,...

  • Official Japanese guidelines for the use of infliximab for rheumatoid arthritis. Miyasaka, Nobuyuki; Takeuchi, Tsutomu; Eguchi, Katsumi // Modern Rheumatology (Springer Science & Business Media B.V.);Mar2005, Vol. 15 Issue 1, p4 

    Differences in ethnic backgrounds as well as in medical and socioeconomic status often affect both the efficacy and adverse effects of medications. Recent data suggest an increased risk of opportunistic infections, especially tuberculosis (TB), among rheumatoid arthritis (RA) patients receiving...

  • Switching biologic agents for uveitis. Dhingra, N.; Morgan, J.; Dick, A. D. // Eye;Sep2009, Vol. 23 Issue 9, p1868 

    PurposeTo observe whether switching between biological agents helps to gain or maintain uveitis remission in cases with sight-threatening refractory uveitis.MethodsWe reviewed the case notes of seven patients with refractory uveitis, who had switched between biological agents. The switch between...

  • Persistent clinical response of infliximab treatment, over a 4-year period in ankylosing spondylitis. Venetsanopoulou, Aliki I.; Voulgari, Paraskevi V.; Alamanos, Yannis; Papadopoulos, Christos G.; Markatseli, Theodora E.; Drosos, Alexandros A. // Rheumatology International;Aug2007, Vol. 27 Issue 10, p935 

    Our aim was to investigate the efficacy, toxicity, and drug discontinuation in patients with ankylosing spondylitis (AS) treated with infliximab. Thirty-five patients with AS, who were enrolled between June 2001 and December 2002 were treated with infliximab. All patients fulfilled the New York...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics